Major Shareholder and CFO Sell-Off: Attention on Inflammatory Disease Drug Developer

BVF Partners, a shareholder owning over 10% of MoonLake Immunotherapeutics (NASDAQ: MLTX), disclosed in an amended Schedule 13D filed on April 2 that it sold millions of shares in the market at the end of March, reducing its stake to approximately 22%. In a report published the same day, the firm stated it has no new aggressive shareholder‐activism plans and will continue its existing investment management and coordinated voting approach.

On April 9–10, Chief Financial Officer Mathias Bodenstedt sold about 80,000 shares under a Rule 10b5-1 trading plan to fund his tax obligations, raising roughly $1.7 million (about KRW 2.1 billion). Filings show he still holds around $23.2 million (about KRW 30 billion) in company stock.

At the end of March, during the American Academy of Dermatology’s annual meeting, MoonLake presented 40-week results from its Phase 3 VELA trial of slonelokimab in hidradenitis suppurativa, providing additional data demonstrating sustained improvements in clinical response and quality-of-life measures. Earlier, in late February, the company reported high response rates in its Phase 2 S-OLARIS trial for radiographic axial spondyloarthritis and expanded its non-dilutive credit facility by up to $500 million, securing capacity for both clinical and financial development.

Headquartered in Zug, Switzerland, MoonLake is a clinical‐stage biotech company developing a single nanobody candidate, slonelokimab, targeting hard-to-treat inflammatory skin and joint diseases such as hidradenitis suppurativa and psoriatic arthritis. The company aims to submit for U.S. approval in the second half of 2026.

With its heavy reliance on a single pipeline and concentration of resources in late-stage trials, shifts in major shareholders’ and management’s holdings, along with clinical and regulatory timelines, remain key variables affecting MoonLake’s share price and valuation.